Hereditary angioedema (HAE) is a genetic disorder that causes episodes of extreme swelling (angioedema), commonly in the face, hands, feet, digestive tract, or upper airways. Symptoms may begin ...

Hereditary angioedema is characterized by unpredictable swelling involving the face, oropharynx, extremities, or abdomen, without hives or pruritus. Laryngeal attacks carry a risk of asphyxiation, ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of ...

6 Hereditary angioedema typically presents as recurrent episodes of nonpitting, nonpruritic edema affecting 3 main areas: subcutaneous tissue (face, upper or lower extremities, genitals ...

Angioedema Control Test Scores rose from 11.3 to 13.9. The percentage of patients with well-controlled disease rose from 67% to 93%. SAN DIEGO — Patients with hereditary angioedema who switched ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexi ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

BioCryst Pharma's Orladeyo has been recommended by NICE as a treatment for the rare disease hereditary angioedema (HAE) in England, Wales and Northern Ireland. Orladeyo (berotralstat ...

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its ...

KalVista's lead asset, sebetralstat, is nearing FDA approval, targeting hereditary angioedema with a first-in-class oral treatment, presenting a significant market opportunity. Strong financial ...